JPMorgan Chase & Co. Has $111.41 Million Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

JPMorgan Chase & Co. lifted its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 13.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,545,473 shares of the medical equipment provider's stock after buying an additional 186,528 shares during the quarter. JPMorgan Chase & Co. owned about 0.68% of Hologic worth $111,413,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in HOLX. Brooklyn Investment Group raised its holdings in Hologic by 14.7% during the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider's stock valued at $82,000 after buying an additional 145 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after acquiring an additional 159 shares in the last quarter. Trivant Custom Portfolio Group LLC raised its stake in shares of Hologic by 2.1% in the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider's stock valued at $602,000 after acquiring an additional 169 shares in the last quarter. UMB Bank n.a. lifted its holdings in Hologic by 4.1% in the 4th quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider's stock worth $343,000 after purchasing an additional 188 shares during the last quarter. Finally, Capital Investment Counsel Inc boosted its position in Hologic by 3.6% during the fourth quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider's stock worth $413,000 after purchasing an additional 200 shares during the period. Institutional investors and hedge funds own 94.73% of the company's stock.

Remove Ads

Hologic Price Performance

Shares of HOLX stock traded up $0.41 during mid-day trading on Monday, reaching $61.27. The company's stock had a trading volume of 4,721,278 shares, compared to its average volume of 1,853,958. The firm's 50-day moving average is $64.07 and its two-hundred day moving average is $72.37. The company has a market cap of $13.75 billion, a P/E ratio of 19.33, a PEG ratio of 2.14 and a beta of 0.82. Hologic, Inc. has a 1-year low of $59.06 and a 1-year high of $84.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on HOLX shares. Stephens restated an "overweight" rating and issued a $84.00 price objective on shares of Hologic in a research note on Thursday, February 6th. Argus lowered shares of Hologic from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Raymond James restated an "outperform" rating and set a $90.00 price target (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. Morgan Stanley dropped their price objective on Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Finally, Leerink Partnrs downgraded Hologic from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Hologic currently has a consensus rating of "Hold" and a consensus target price of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.